Charles Lowenstein, MD
Cardiovascular Disease · Baltimore, MDNPI 1770529083
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $12,988 of the $13,384 with a category attached, or 97.0%. Canon Medical Systems Corporation accounts for 98.7% of it on its own, with 1 other manufacturer making up the rest.
Across 4 payments — averaging $3345.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Canon Medical Systems Corporation$13K
- Canon Healthcare USA, Inc.$173
Across 1 payment — averaging $530,356 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$530K
What the payments were for
- Travel & lodging$12,98897%
- Food & beverage$3963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Canon Medical Systems Corporation | 3 | $13,211 |
| Canon Healthcare USA, Inc. | 1 | $173 |
How this compares
$13,384 in reported general payments places this provider in the 85th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $29,363 |
| FarxigaDapagliflozin Propanediol | 11 | $6,899 |
| Atorvastatin Calcium | 80 | $1,046 |
| Ezetimibe | 20 | $767 |
| Losartan Potassium | 78 | $727 |
| Rosuvastatin Calcium | 49 | $447 |
| Carvedilol | 71 | $447 |
| Amlodipine Besylate | 50 | $384 |
| Metoprolol Succinate | 34 | $301 |
| Chlorthalidone | 22 | $295 |
| Hydrochlorothiazide | 67 | $159 |
| Lisinopril | 24 | $150 |
| Spironolactone | 13 | $105 |
| Furosemide | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Baltimore
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Charles CummingsBaltimore$114K
- John RickardBaltimore$109K
- Christopher DefilippiBaltimore$101K
- David KassBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.